You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD5 CAR-T

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

T-cell Acute Lymphoblastic Leukemia Trial in Beijing (CD5 CAR-T)

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • CD5 CAR-T
  • Beijing, Beijing, China
    Xuanwu Hospital Capital Medical University
Oct 23, 2022

T-Cell Acute Lymphoblastic Leukemia/Lymphoma Trial in Beijing (CD5 CAR T (CT125B))

Recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoma
  • CD5 CAR T (CT125B)
  • Beijing, Beijing, China
    Beijing Gaobo Boren Hospital
Aug 3, 2022

Lymphoma Trial in Seattle (biological, other, procedure)

Not yet recruiting
  • Lymphoma
  • Immune Globulin Infusion (Human), 10% Solution
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 21, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
  • +4 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Sep 22, 2022

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • +3 more
  • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Jun 26, 2022

T-cell Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma Trial in Shenzhen (anti-CD5 CAR T cells)

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • T-cell Non-Hodgkin Lymphoma
  • anti-CD5 CAR T cells
  • Shenzhen, Guangdong, China
    Peking University Shenzhen Hospital
Feb 27, 2021

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • B-cell Chronic Lymphocytic Leukemia
  • Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
  • +3 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

Hiv Trial in Philadelphia (CD4 CAR+CCR5 ZFN T-cells)

Active, not recruiting
  • Hiv
  • CD4 CAR+CCR5 ZFN T-cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jan 6, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Duarte

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia Trial in Vancouver, Ottawa (CLIC-1901)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • CLIC-1901
  • Vancouver, British Columbia, Canada
  • +1 more
Mar 26, 2022

Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL) Trial in Canada, United States (CC-97540)

Active, not recruiting
  • Lymphoma Non-Hodgkin
  • +2 more
  • CC-97540
  • Birmingham, Alabama
  • +13 more
Oct 28, 2022

Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Lymphoma
  • CD70-targeting CAR-T cells
  • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 9, 2023

Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia Trial in Duarte

Active, not recruiting
  • Adult Acute Myeloid Leukemia in Remission
  • +12 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Solid Tumor, Adult
  • CD70-targeting CAR-T cells
  • Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 8, 2023

Systemic Lupus Erythematosus Trial (CD19 CAR-T cell infusion)

Not yet recruiting
  • Systemic Lupus Erythematosus
  • CD19 CAR-T cell infusion
  • (no location specified)
Oct 24, 2023

CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)

Recruiting
  • CD70-positive Advanced Urologic Neoplasms
  • Anti-CD70 CAR-T cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Aug 11, 2023

Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer Trial in Nanchang (CD70 CAR-T cells)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • CD70 CAR-T cells
  • Nanchang, Jiangxi, China
    The First Affiliated Hospital of Nanchang University
Aug 23, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Mar 8, 2022

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023